宫颈癌患者血清SCC、CA125及PDL1水平与细胞凋亡指数相关性的研究

Study on the correlation between the changes of serum SCC, CA125 and PDL1 levels and clinicopathological characteristics and apoptosis index in patients with cervical cancer

摘要

目的 探讨宫颈癌患者不同临床病理特征的血清鳞状细胞癌抗原(SCC)、糖链抗原125(CA125)及可溶程序性死亡分子1(PDL1)水平的变化,以及其与细胞凋亡指数的相关性。方法 选取2020年10月至2022年2月在湖北民族大学附属民大医院就诊的76例宫颈癌患者为实验组,另选同时期在院进行体检的76例健康妇女为对照组.采用电化学发光法测定两组的血清SCC、CA125及PDL1水平;采用流式细胞术检测两组的细胞凋亡指数;比较两组的血清SCC、CA125及PDL1水平及细胞凋亡指数,分析血清SCC、CA125及PDL1水平与细胞凋亡指数的相关性。结果 实验组的血清SCC、CA125及PDL1水平均高于对照组,差异均有统计学意义(t值分别为28.539、18.713、14.414,P<0.05).实验组的细胞凋亡指数(6.87±2.89)高于对照组的细胞凋亡指数(2.44±0.56),差异有统计学意义(t=13.132,P<0.001).临床分期为Ⅲ~Ⅳ期宫颈癌患者的血清SCC、CA125及PDL1水平均高于Ⅰ~Ⅱ期者(t值分别为14.444、6.047、8.401,P<0.05);肿瘤分化程度为高分化宫颈癌患者的血清SCC、CA125及PDL1水平均高于中分化和低分化者(F值分别为177.105、32.848、31.386,P<0.05);淋巴结转移宫颈癌患者的血清SCC、CA125及PDL1水平均高于淋巴结未转移者(t值分别为6.659、7.356、6.460,P<0.05);不同病理分类(鳞状细胞癌与腺癌)宫颈癌患者的血清SCC、CA125及PDL1水平比较差异均无统计学意义(P>0.05).宫颈癌患者的血清SCC、CA125及PDL1水平均与细胞凋亡指数呈正相关(r值分别为0.689、0.662、0.495,P<0.05)。结论 宫颈癌患者血清SCC、CA125及PDL1水平显著升高,与临床分期、肿瘤分化程度及淋巴结转移密切相关,且均与细胞凋亡指数呈正相关,其可为临床宫颈癌的诊断治疗及监测提供参考.

Abstract

Objective To study the changes of serum SCC, CA125 and PDL1 levels in patients with cervical cancer and analyze their correlation with clinicopathological characteristics and apoptosis index. Methods 76 patients with cervical cancer who came to our hospital from October 2020 to February 2022 were selected as the experimental group, and 76 healthy women who came to our hospital for physical examination in the same period were selected as the control group. Compare the general data of the two groups of subjects; Serum SCC, CA125 and PDL1 levels were measured by electrochemiluminescence method; The apoptosis index of the two groups was detected by flow cytometry; To analyze the relationship between the changes of serum SCC, CA125 and PDL1 levels and clinicopathological features and apoptosis index. Results The levels of serum SCC, CA125, PDL1 and apoptosis index in the experimental group were significantly higher than those in the control group (P<0.05). The higher the clinical stage, tumor differentiation and lymph node metastasis of cervical cancer patients, the higher the serum levels of SCC, CA125 and PDL1. The clinical stage, tumor differentiation and lymph node metastasis were closely related to lymph node metastasis (P<0.05); There was no significant difference between pathological classification of cervical cancer patients and serum SCC, CA125 and PDL1 levels (P>0.05). Serum SCC, CA125 and PDL1 levels in patients with cervical cancer were positively correlated with apoptosis index (r=0.689, 0.662, 0.495, P<0.05). Conclusion Serum SCC, CA125 and PDL1 levels in patients with cervical cancer are significantly increased, which is closely related to clinical stage, tumor differentiation and lymph node metastasis, and is positively related to apoptosis index, which provides reference for clinical diagnosis, treatment and monitoring of cervical cancer.

关键词

宫颈癌 / 鳞状细胞癌抗原 / 糖链抗原125 / 可溶程序性死亡分子1 / 细胞凋亡指数

Key words

cervical cancer / SCC / CA125 / PDL1 / apoptosis index

参考文献

[1] 穆建玲, 姚昔艳. 血清人附睾蛋白4水平与宫颈癌患者临床特征的关系[J]. 癌症进展, 2021, 19(23): 2457-2460.

[2] Hu Z, Ma D. The precision prevention and therapy of HPV-related cervical cancer: new concepts and clinical implications[J]. Cancer Med, 2018, 7(10): 5217-5236.

[3] 王恺彬, 郑建军, 王艳君. SMIM22、miR-150-5p在子宫内膜癌组织中的表达及与预后的关系[J]. 中国优生与遗传杂志, 2022, 30(5): 866-869.

[4] 王巧妹, 陈建红. 宫颈癌组织中PGRMC1表达水平与临床病理特征、预后的关系[J]. 国际检验医学杂志, 2021, 42(22): 2791-2794.

[5] Laengsri V, Kerdpin U, Plabplueng C, et al. Cervical cancer markers: epigenetics and microRNAs[J]. Lab Med, 2018, 49(2): 97-111.

[6] 袁红琴, 王霞, 刘楷东. 肿瘤体积变化、鳞状细胞癌抗原、癌胚抗原、糖类抗原125与宫颈癌同步放化疗患者预后的关系及分析[J]. 中国医师进修杂志, 2022, 45(5): 385-392.

[7] 孙一, 郭婷. 保留自主神经功能的子宫广泛切除术治疗宫颈癌对血清肿瘤标志物及性功能的影响[J]. 中国性科学, 2023, 32(2): 92-96.

[8] Niu M, Liu Y, Yi M, et al. Biological characteristics and clinical significance of soluble PD-1/PD-L1 and exosomal PD-L1 in cancer[J]. Front Immunol, 2022, 13: 827921.

[9] Kashyap D, Garg V K, Goel N. Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis[J]. Adv Protein Chem Struct Biol, 2021, 125: 73-120.

[10] 周晓莉, 赵嫦娥, 成珺婷, 等. 老年宫颈癌患者血清NO和Gal-9检测及与凋亡指数的相关性分析[J]. 河北医药, 2019, 41(15): 2321-2324.

[11] 陈志军, 邓雪莉, 陈慧. 术前外周血SII、NLR、PLR对宫颈癌淋巴结转移的评估价值[J]. 中国妇幼健康研究, 2023, 34(4): 33-39.

[12] 陈珊珊, 杨睿, 肖涛, 等. 血清肿瘤标志物水平在宫颈癌病情监测及预后评估中的价值[J]. 中国肿瘤临床与康复, 2022, 29(8): 965-968.

[13] Lee Sea Won, Hong Ji Hyung, Yu Mina, et al. Serum conversion pattern of SCC-Ag levels between pre- and post-chemoradiotherapy predicts recurrence and metastasis in cervical cancer: a multi-institutional analysis[J]. Clin Exp Metastasis, 2021, 38(5): 467-474.

[14] Yang W J, Wang L, Obstetrics DO. The diagnostic value and clinical significance of combining serum squamous cell carcinoma antigen with IL-6 and TGF-β in patients with cervical cancer[J]. Labeled Immunoassays and Clinical Medicine, 2017, 24(1): 77-80.

[15] 余晓辉, 周阳春. SCCA、TSGF和CA125在宫颈癌患者血清中的表达水平及其与宫颈癌分期的相关性分析[J]. 国际检验医学杂志, 2018, 39(9): 1131-1134.

[16] Wu Q, Jiang L, Li SC, et al. Small molecule inhibitors targeting the PD-1/PD-L1 signaling pathway[J]. Acta Pharmacol Sin, 2021, 42(1): 1-9.

[17] Meng Y, Liang H, Hu J, et al. PDL1 expression correlates with tumor infiltrating lymphocytes and response to neoadjuvant chemotherapy in cervical cancer[J]. J Cancer, 2018, 9(16): 2938-2945.

[18] Carneiro B A, El-Deiry W S. Targeting apoptosis in cancer therapy[J]. Nat Rev Clin Oncol, 2020, 17(7): 395-417.